Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy

References

• Carroll A, Dyck PJ, de Carvalho M, et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry. 2022;93(6):668–678. doi: 10.1136/jnnp-2021-327909
   PubMedGoogle Scholar
• Plante-Bordeneuve V. Transthyretin familial amyloid polyneuropathy: an update. J Neurol. 2018;265(4):976–983. doi: 10.1007/s00415-017-8708-4
   PubMed Web of Science ®Google Scholar
• Planté-Bordeneuve V, Gorram F, Olsson M, et al. A multicentric study of the disease risks and first manifestations in hereditary transthyretin amyloidosis (ATTRv): insights for an earlier diagnosis. Amyloid. 2023;30(3):313–320. doi: 10.1080/13506129.2023.2178891
   PubMed Web of Science ®Google Scholar
• Mariani L-L, Lozeron P, Théaudin M, et al. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol. 2015;78:901–916. doi: 10.1002/ana.24519
   PubMed Web of Science ®Google Scholar
• Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2022;118:3517–3535. doi: 10.1093/cvr/cvac119
   Web of Science ®Google Scholar
• Ericzon B-G, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99(9):1847–1854. doi: 10.1097/TP.0000000000000574
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ando Y, Okamoto S, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology. 2012;78:637–643. doi: 10.1212/WNL.0b013e318248df18
   PubMed Web of Science ®Google Scholar
• Olofsson B-O, Backman C, Karp K, et al. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation. 2002;73(5):745–751. doi: 10.1097/00007890-200203150-00015
   PubMed Web of Science ®Google Scholar
• Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology. 2010;75(4):324–327. doi: 10.1212/WNL.0b013e3181ea15d4
   PubMed Web of Science ®Google Scholar
• Bulawa CE, Connelly S, DeVit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci. 2012;109(24):9629–9634. doi: 10.1073/pnas.1121005109
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy. Neurology. 2012;79:785–792. doi: 10.1212/WNL.0b013e3182661eb1
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260:2802–2814. doi: 10.1007/s00415-013-7051-7
   PubMed Web of Science ®Google Scholar
• Planté-Bordeneuve V, Gorram F, Salhi H, et al. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. J Neurol. 2017;264(2):268–276. doi: 10.1007/s00415-016-8337-3
   PubMed Web of Science ®Google Scholar
• Cortese A, Vita G, Luigetti M, et al. Monitoring effectiveness and safety of tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol. 2016;263(5):916–924. doi: 10.1007/s00415-016-8064-9
   PubMed Web of Science ®Google Scholar
• Monteiro C, Mesgazardeh JS, Anselmo J, et al. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight. 2019;4:e126526. doi: 10.1172/jci.insight.126526.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. doi: 10.1056/NEJMoa1805689
   PubMed Web of Science ®Google Scholar
• Damy T, Garcia-Pavia P, Hanna M, et al. Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021;23(2):277–285. doi: 10.1002/ejhf.2027
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658–2667. doi: 10.1001/jama.2013.283815
   PubMed Web of Science ®Google Scholar
• Lohrmann G, Pipilas A, Mussinelli R, et al. Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis. J Card Fail. 2020;26(9):753–759. doi: 10.1016/j.cardfail.2019.11.024
   PubMed Web of Science ®Google Scholar
• Brannagan TH, Berk JL, Gillmore JD, et al. Liver‐directed drugs for transthyretin-mediated amyloidosis. J Peripher Nerv Syst. 2022;27:228–237. doi: 10.1111/jns.12519
   PubMed Web of Science ®Google Scholar
• Bennett CF. Therapeutic antisense oligonucleotides are coming of age. Annu Rev Med. 2019;70(1):307–321. doi: 10.1146/annurev-med-041217-010829
   PubMedGoogle Scholar
• Zhang MM, Bahal R, Rasmussen TP, et al. The growth of siRNA-based therapeutics: updated clinical studies. Biochem Pharmacol. 2021;189:114432. doi: 10.1016/j.bcp.2021.114432.
   PubMed Web of Science ®Google Scholar
• Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol. 2017;35(3):222–229. doi: 10.1038/nbt.3802
   PubMed Web of Science ®Google Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31. doi: 10.1056/NEJMoa1716793
   PubMed Web of Science ®Google Scholar
• Brannagan TH, Coelho T, Wang AK, et al. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update. J Neurol. 2022;269(12):6416–6427. doi: 10.1007/s00415-022-11276-8
   PubMed Web of Science ®Google Scholar
• Dasgupta NR, Rissing SM, Smith J, et al. Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2020;27:52–58. doi: 10.1080/13506129.2019.1685487
   PubMed Web of Science ®Google Scholar
• Benson MD, Dasgupta NR, Rissing SM, et al. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2017;24:219–225. doi: 10.1080/13506129.2017.1374946
   PubMed Web of Science ®Google Scholar
• MD RHF. 24 month open label study of the tolerability and efficacy of an antisense oligonucleotide (inotersen) in patients with transthyretin (TTR) amyloid cardiomyopathy. Available from: https://clinicaltrials.gov/ct2/show/NCT03702829.
   Google Scholar
• Ioannou A, Fontana M, Gillmore JD. RNA targeting and gene editing strategies for transthyretin amyloidosis. BioDrugs Clin Immunother Biopharm Gene Ther. 2023;37:127–142. doi: 10.1007/s40259-023-00577-7
   Google Scholar
• Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819–829. doi: 10.1056/NEJMoa1208760
   PubMed Web of Science ®Google Scholar
• Zhang X, Goel V, Robbie GJ. Pharmacokinetics of patisiran, the first approved RNA interference therapy in patients with hereditary transthyretin-mediated amyloidosis. J Clin Pharmacol. 2020;60(5):573–585. doi: 10.1002/jcph.1553
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21. doi: 10.1056/NEJMoa1716153
   PubMed Web of Science ®Google Scholar
• Adams D, Polydefkis M, González-Duarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol. 2021;20(1):49–59. doi: 10.1016/S1474-4422(20)30368-9
   PubMed Web of Science ®Google Scholar
• Ticau S, Aldinc E, Polydefkis M, et al. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study. Amyloid. 2023;1–11. doi: 10.1080/13506129.2023.2232520
   PubMedGoogle Scholar
• Di Stefano V, Fava A, Gentile L, et al. Italian real-life experience of patients with hereditary transthyretin amyloidosis treated with Patisiran. Pharmacogenomics Pers Med. 2022;15:499–514. doi: 10.2147/PGPM.S359851
   PubMed Web of Science ®Google Scholar
• Maurer MS, Kale P, Fontana M, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389(17):1553–1565. doi: 10.1056/NEJMoa2300757
   PubMed Web of Science ®Google Scholar
• Merlini G. A step forward in solving amyloidosis. N Engl J Med. 2023;389(17):1615–1617. doi: 10.1056/NEJMe2309308
   PubMed Web of Science ®Google Scholar
• Habtemariam BA, Karsten V, Attarwala H, et al. Single‐dose pharmacokinetics and pharmacodynamics of transthyretin targeting N‐acetylgalactosamine–small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther. 2021;109(2):372–382. doi: 10.1002/cpt.1974
   PubMed Web of Science ®Google Scholar
• Berk C, Civenni G, Wang Y, et al. Pharmacodynamic and pharmacokinetic properties of full phosphorothioate small interfering RNAs for gene silencing in vivo. Nucleic Acid Ther. 2021;31:237–244. doi: 10.1089/nat.2020.0852
   PubMed Web of Science ®Google Scholar
• An G. Pharmacokinetics and pharmacodynamics of GalNAc-conjugated siRNAs. J Clin Pharmacol. 2023;64(1):45–57. doi: 10.1002/jcph.2337
   PubMed Web of Science ®Google Scholar
• Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2022;30(1):18–26. doi: 10.1080/13506129.2022.2091985
   Web of Science ®Google Scholar
• Obici L, Ajroud-Driss S, Lin K-P, et al. Impact of vutrisiran on quality of life and physical function in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Neurol Ther. 2023;12(5):1759–1775. doi: 10.1007/s40120-023-00522-4
   PubMed Web of Science ®Google Scholar
• Garcia-Pavia P, Gillmore JD, Kale P, et al. HELIOS-A: 18-month exploratory cardiac results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis. ESC Heart Failure. 2022;15(1):31–32. doi: 10.1016/j.acvdsp.2022.10.056
   Google Scholar
• Alnylam Pharmaceuticals. HELIOS-B: a phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (ATTR amyloidosis with cardiomyopathy). Available from: https://clinicaltrials.gov/ct2/show/NCT04153149
   Google Scholar
• Keam SJ. Vutrisiran: First approval. Drugs. 2022;82:1419–1425. doi: 10.1007/s40265-022-01765-5
   PubMed Web of Science ®Google Scholar
• EMA. Amvuttra. European Medicines Agency. 2022. Available from. https://www.ema.europa.eu/en/medicines/human/EPAR/amvuttra
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Evidence | vutrisiran for treating hereditary transthyretin-related amyloidosis | guidance. NICE; 2023. Available from: https://www.nice.org.uk/guidance/ta868/evidence
   Google Scholar
• de Santé HA. AMVUTTRA (vutrisiran) - first evaluation. Haute Aut. Santé. Available from: https://www.has-sante.fr/jcms/p_3402366/fr/amvuttra-vutrisiran-amylose-hereditaire-a-transthyretine.
   Google Scholar
• Nie T, Heo Y-A, Shirley M. Vutrisiran: a review in polyneuropathy of hereditary transthyretin-mediated amyloidosis. Drugs. 2023;83:1425–1432. doi: 10.1007/s40265-023-01943-z
   PubMed Web of Science ®Google Scholar
• Diep JK, Yu RZ, Viney NJ, et al. Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis. Br J Clin Pharmacol. 2022;88(12):5389–5398. doi: 10.1111/bcp.15468
   PubMed Web of Science ®Google Scholar
• Coelho T, Marques W, Dasgupta NR, et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA. 2023;330(15):1448. doi: 10.1001/jama.2023.18688
   PubMed Web of Science ®Google Scholar
• Dyck PJB, González-Duarte A, Obici L, et al. Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS + 7. J Neurol Sci. 2019;405:116424. doi: 10.1016/j.jns.2019.116424
   PubMed Web of Science ®Google Scholar
• Ionis Pharmaceuticals, Inc. A phase 3 global, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of ION-682884 in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR CM). Available from: https://clinicaltrials.gov/ct2/show/NCT04136171
   Google Scholar
• Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493–502. doi: 10.1056/NEJMoa2107454
   PubMed Web of Science ®Google Scholar
• Intellia Therapeutics. Phase 1 two-part (open-label, single ascending dose (part 1) and open-label, single dose expansion (part 2)) study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of NTLA-2001 in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and patients with transthyretin amyloidosis-related cardiomyopathy (ATTR-CM) Available from: https://clinicaltrials.gov/ct2/show/NCT04601051
   Google Scholar
• Polydefkis M, Birklein F, Sekijima Y, et al. Comparison of efficacy outcomes with vutrisiran vs. Patisiran in hATTR amyloidosis with polyneuropathy: post-hoc analysis of the HELIOS-A study (S14.003). Lippincott Williams & Wilkins; 2023. Available from: http://www.neurology.org/lookup/doi/10.1212/WNL.0000000000202920
   Google Scholar
• González-Duarte A. Novel treatments for hereditary ATTRv amyloidosis. JAMA. 2023;330(15):1433. doi: 10.1001/jama.2023.15087
   PubMed Web of Science ®Google Scholar
• Merkel M, Danese D, Chen C, et al. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opin Pharmacother. 2023;24(10):1205–1214. doi: 10.1080/14656566.2023.2215925
   PubMed Web of Science ®Google Scholar
• Watanabe T, Takihara Y, Jono H, et al. Silencing of ocular transthyretin, a gene responsible for hereditary transthyretin amyloidosis, by intravitreal injection of an siRNA conjugate into rabbit eyes. Biochem Biophys Res Commun. 2024;694:149397. doi: 10.1016/j.bbrc.2023.149397
   PubMed Web of Science ®Google Scholar
• Alnylam Pharmaceuticals. A phase 1, randomized, double-blind, placebo controlled, single-ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously administered ALN-TTRSC04 in healthy subjects. Available from: https://clinicaltrials.gov/study/NCT05661916
   Google Scholar
• Garcia-Pavia P, Aus Dem Siepen F, Donal E, et al. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N Engl J Med. 2023;389(3):239–250. doi: 10.1056/NEJMoa2303765
   PubMed Web of Science ®Google Scholar
• Wardhere A, Bampatsias D, Fine N, et al. Heterogeneous worldwide access and pricing of Tafamidis. Amyloid. 2023;1–3. doi: 10.1080/13506129.2023.2263620
   PubMed Web of Science ®Google Scholar